3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
17
Stomach Neoplasms
8
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Rectal Neoplasms
5
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
3
Nasopharyngeal Carcinoma
3
Esophageal Neoplasms
3
Uterine Cervical Neoplasms
2
Solid Tumor
2
Recurrence
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Endometrial Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Resectable NSCLC
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Metastatic Gastroesophageal Junction Adenocarcinoma
1
Meningeal Carcinomatosis
1
MSI-H
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Oxaliplatin
19
pembrolizumab
13
Fluorouracil
12
Leucovorin
11
Capecitabine
11
Paclitaxel
10
Gemcitabine
8
Docetaxel
8
zolbetuximab
6
cemiplimab
6
Cisplatin
6
Albumin-Bound Paclitaxel
6
durvalumab
5
Ramucirumab
5
Radiotherapy
5
Irinotecan
4
Cyclophosphamide
4
130-nm albumin-bound paclitaxel
4
trastuzumab deruxtecan
3
tislelizumab
3
lenvatinib
3
enzalutamide
3
darolutamide
3
Trastuzumab
3
Taxes
3
S 1 (combination)
3
Radiosurgery
3
Pemetrexed
3
Nivolumab
3
Carboplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
sintilimab
×
1 year
×
Clear all
NCT05161572
2025-06-18
NeoRacing
Fudan University
Phase 2
Terminated
6 enrolled